Reorganizing its generics business strategy to target 60% instead of 80% of drugs coming off patent and reallocating resources to complex generics will help Teva offset base business erosion and ...
Developed by Ascentage Pharma, lisaftoclax is a novel orally available Bcl-2 inhibitor with clinical benefits for an array of hematologic malignancies and solid tumors. At this year's ASH Annual ...